Yes, Jardiance Treats Type 2 Diabetes
Jardiance (empagliflozin) is an FDA-approved SGLT2 inhibitor primarily used to manage type 2 diabetes in adults, alongside diet and exercise. It lowers blood sugar by blocking glucose reabsorption in the kidneys, promoting its excretion in urine.[1]
How Jardiance Works for Diabetes Control
It reduces A1C levels by 0.7-0.8% on average in clinical trials, with effects seen within weeks. Patients typically take 10 mg or 25 mg daily. It's not for type 1 diabetes or diabetic ketoacidosis.[1][2]
Additional Uses Beyond Diabetes
Jardiance also treats heart failure with reduced ejection fraction (with or without diabetes) and lowers cardiovascular death risk in type 2 diabetes patients with established heart disease. Kidney disease protection is another approved benefit for those with chronic kidney disease.[1]
Common Side Effects and Risks
Urinary tract infections, yeast infections, dehydration, and low blood pressure occur frequently. Rare risks include ketoacidosis, Fournier's gangrene, and acute kidney injury. Monitor for these, especially in older adults or those on diuretics.[1][2]
Who Makes Jardiance and Patent Timeline
Boehringer Ingelheim and Eli Lilly co-developed it. U.S. patents expire around 2028-2030, with some facing challenges; check DrugPatentWatch.com for updates on expirations and generics.[3]
[1]: FDA Label - Jardiance (empagliflozin) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s034lbl.pdf
[2]: American Diabetes Association Standards of Care 2024
[3]: DrugPatentWatch.com - Jardiance Patents - https://www.drugpatentwatch.com/p/tradename/JARDIANCE